Cyclarity's UDP-003 completed Phase 1 safety testing in 72 healthy volunteers, demonstrating excellent tolerability with no serious adverse events and achieving its primary mechanism: selective extraction of 7-ketocholesterol (7KC), a toxic oxidized cholesterol variant, into urine. The compound targets the root cause of atherosclerosis by converting dysfunctional foam cells back into active macrophages capable of clearing arterial plaque.
Key Points
- UDP-003 showed no serious adverse events across all tested doses in humans.
- Drug achieved perfect dose-response for 7KC excretion in urine—a novel finding.
- Mechanism targets foam cell dysfunction rather than conventional cholesterol or inflammation.
Longevity Analysis
Most cardiovascular interventions address downstream markers like LDL or inflammation without resolving the cellular pathology driving plaque formation. UDP-003 operates at an earlier causal layer by neutralizing 7-ketocholesterol, an oxidized byproduct that accumulates inside macrophages and locks them into a dysfunctional state. By restoring macrophage function and enabling plaque clearance, this approach addresses a fundamental problem in how the body's defense systems respond to lipid oxidation. Phase 2 will determine whether this mechanistic success translates to measurable improvements in cardiovascular outcomes, but the safety and target engagement data position this therapy as a potential shift in atherosclerosis treatment philosophy.
Original published by LifeSpan.io, by Steve Hill.